Tripeptide-29 Peptide

Tripeptide-29 (Gly-His-Lys analog) is a collagen fragment that acts as a matrikine — a signaling peptide released from extracellular matrix breakdown. It stimulates fibroblasts to produce new collagen I and III by mimicking the natural wound-healing signal that triggers matrix remodeling.

Tripeptide-29 is a synthetic collagen-mimetic tripeptide based on the repeating Gly-X-Y motif that constitutes the primary structural backbone of fibrillar collagens, particularly collagen types I and III. Its proposed mechanism of action centers on three interrelated pathways: matrikine signaling, fibroblast stimulation, and physical templating of nascent collagen triple helices. Understanding each pathway helps clarify why short collagen-derived peptides are studied so heavily in dermal research models.

Matrikine Signaling and Fibroblast Activation

Matrikines are bioactive fragments derived from extracellular matrix (ECM) proteins that act as endogenous signaling molecules. When collagen is degraded by matrix metalloproteinases (MMPs) during wound healing or photoaging, short peptide fragments are liberated that bind to fibroblast surface receptors, triggering feedback loops that re-initiate ECM synthesis. Tripeptide-29 has been hypothesised to mimic these endogenous fragments, engaging fibroblasts to upregulate procollagen I (COL1A1) and procollagen III (COL3A1) gene expression. This biomimetic strategy underpins the entire matrikine class, which also includes GHK, KTTKS (Matrixyl), and GEKG.

Collagen Triple Helix Templating

Native collagen assembles into a right-handed triple helix composed of three polyproline-II-like chains held together by hydrogen bonds between glycine amide protons and adjacent carbonyl groups. Research on collagen-mimetic peptides (CMPs) has shown that short Gly-Pro-Hyp and Gly-X-Y sequences can hybridize with partially denatured collagen strands, acting as molecular “splints” that stabilize damaged fibrils. Preclinical studies suggest tripeptide motifs can intercalate into compromised collagen networks, potentially supporting structural recovery in photoaged or wounded tissue models.

Modulation of MMP Activity and Oxidative Stress

Photoaging and chronological aging are characterised by elevated MMP-1 and MMP-3 expression, which degrade dermal collagen faster than fibroblasts can replace it. In vitro work on related collagen tripeptides has demonstrated downregulation of MMP-1 transcription and concurrent upregulation of tissue inhibitor of metalloproteinases (TIMP-1) following UV exposure. Tripeptide-29 is studied within this paradigm as a candidate for shifting the dermal protease-antiprotease balance toward matrix preservation.

High Dermal Penetration Profile

One of the principal research rationales for using a tripeptide rather than larger collagen hydrolysates is molecular size. At under 350 Da, tripeptides are small enough to penetrate the stratum corneum via the intercellular lipid route, in contrast to native collagen (~300 kDa) which cannot traverse intact skin. This penetration advantage has been documented in Franz cell diffusion studies of related Gly-Pro-Hyp tripeptides and is considered a key reason small collagen fragments are favoured over hydrolysed collagen in topical research formulations.

Comparison to Related Matrikines

While GHK-Cu primarily signals through copper-dependent remodeling pathways and Matrixyl (pal-KTTKS) relies on a lipidated propeptide fragment of type I collagen, Tripeptide-29 is hypothesised to act as a direct collagen-helix mimetic. This positions it as complementary — rather than redundant — to other matrikines in comparative dermal research panels.

Tripeptide-29 is a cosmetic ingredient designation referring to a synthetic collagen-mimetic tripeptide built on the Gly-X-Y motif characteristic of fibrillar collagen. As supplied for dermal research, the raw peptide may be co-formulated with stabilisers, solubilisers, or carrier matrices depending on intended application (lyophilized powder versus topical solution). Researchers should refer to the supplier-specific Certificate of Analysis (COA) for the exact composition of any given lot. The table below summarises the principal components typically associated with Tripeptide-29 research preparations.

Physical & Handling Specifications

Because Tripeptide-29 is defined by its INCI designation rather than a single fixed molecular formula, no universal CAS number applies across all suppliers. Researchers requiring exact structural data for publication should request the specific sequence and synthesis report from their material supplier.

Tripeptide-29 is supplied as a lyophilized peptide powder intended exclusively for laboratory and cosmetic-formulation research use. Because the Gly-Pro-Hyp sequence is hygroscopic and the imino acid hydroxyproline is moderately oxidation-sensitive at elevated temperatures, careful handling is required to preserve peptide integrity and consistent assay results.

Pre-Reconstitution Equilibration

Before opening the vial, allow it to equilibrate to room temperature (approximately 20–25 °C) for 20–30 minutes while still sealed. This prevents condensation of atmospheric moisture onto the lyophilized cake when the cold vial is exposed to ambient humidity. Briefly centrifuge the vial (1,000 × g, 30 seconds) to consolidate any powder that may have shifted during shipping.

Recommended Reconstitution Protocol

1. Select a reconstitution solvent appropriate for downstream application: sterile water for injection, 0.9% sodium chloride, or bacteriostatic water are commonly used in research contexts. For topical formulation studies, a low-pH aqueous buffer (pH 5.0–6.0) is often preferred to match skin physiology.
2. Inject the chosen solvent down the side wall of the vial rather than directly onto the peptide cake.
3. Allow the vial to stand undisturbed for 2–3 minutes to permit gentle hydration.
4. Swirl gently to dissolve. Do not vortex or shake vigorously — mechanical agitation can induce peptide aggregation and foaming, reducing functional concentration.
5. Once fully clear, the solution can be aliquoted into low-binding microtubes to avoid repeat freeze-thaw cycles.

Concentration Calculation

For a typical 10 mg vial:

• 10 mg + 1.0 mL solvent → 10 mg/mL stock
• 10 mg + 2.0 mL solvent → 5 mg/mL stock
• 10 mg + 10.0 mL solvent → 1 mg/mL working solution

Compound-Specific Notes

Tripeptide-29 contains hydroxyproline, an imino acid prone to slow oxidation under prolonged exposure to dissolved oxygen and elevated temperature. To preserve potency:

• Prepare working solutions immediately before use whenever possible.
• Where extended storage of reconstituted solution is required, purge headspace with an inert gas (nitrogen or argon) before sealing.
• Avoid prolonged exposure to alkaline pH (> 8.0), which can accelerate peptide bond hydrolysis at the proline-hydroxyproline junction.
• Use low-binding plasticware to minimize peptide adsorption losses at low concentrations.

All reconstitution should be performed using aseptic technique in a clean laboratory environment. Personal protective equipment, including nitrile gloves and safety eyewear, is recommended.

Proper storage of Tripeptide-29 is essential to maintain peptide integrity, consistent research reproducibility, and accurate assay results. The Gly-Pro-Hyp sequence is relatively stable compared to longer peptides containing labile amino acids such as methionine or cysteine, but appropriate storage conditions remain important for prolonged shelf life and to prevent hydroxyproline degradation.

Lyophilized Powder Storage

• Long-term storage: Store the sealed, lyophilized vial at –20 °C in a frost-free freezer. Under these conditions, Tripeptide-29 is expected to remain stable for 24–36 months from the date of manufacture.
• Short-term storage: The vial may be held at 2–8 °C for periods of up to several weeks if active use is anticipated.
• Transit conditions: Tripeptide-29 tolerates brief exposure to ambient room temperature (up to ~25 °C) for shipping periods of 5–7 days without measurable loss of activity, owing to the inherent stability of short proline-rich peptides.

Reconstituted Solution Storage

• 2–8 °C refrigeration: Reconstituted Tripeptide-29 in sterile aqueous solvent retains potency for approximately 3–4 weeks when stored in a sealed, light-protected vial.
• –20 °C freezing: For extended storage, aliquot the reconstituted peptide into single-use volumes and freeze at –20 °C. Stability under these conditions is typically 6 months.
• Avoid repeated freeze-thaw cycles: Each thaw cycle introduces hydrolysis and oxidation risk. Aliquoting at the time of reconstitution minimizes this issue.

Stability Considerations Specific to Tripeptide-29

The hydroxyproline residue in Tripeptide-29 confers good resistance to proteolytic cleavage but can undergo slow oxidative degradation under prolonged exposure to air and ambient light. Key considerations:

• Light sensitivity: Minor — store vials in opaque or amber-tinted containers to mitigate any photodegradation risk.
• pH stability range: Most stable in the pH 4.0–7.0 window. Avoid prolonged storage at extremes of pH.
• Moisture sensitivity: The lyophilized form is hygroscopic; ensure the vial seal is intact and limit exposure to humid air during handling.

This product is supplied strictly for in-vitro research and cosmetic formulation development. It is not intended for human use, therapeutic application, or in-vivo administration. All storage and handling should follow good laboratory practice (GLP) standards and institutional safety guidelines.